{"filing":{"accession_number":"0001193125-26-230711","cik":"0001563577","ticker":null,"company_name":"Galera Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"d78370d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526230711/d78370d8k.htm"},"classifications":[{"id":147,"accession_number":"0001193125-26-230711","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Company converted 42,839.11 shares of Series B Non-Voting Convertible Preferred Stock into 42,839,103 shares of common stock on May 15, 2026, resulting in a substantial increase in common share count (approximately 1,000x conversion ratio). This mandatory conversion of preferred stock into common stock is a dilutive issuance that materially increases the equity base and would affect a reasonable investor's assessment of ownership dilution and voting power, even though the conversion was contractually mandated under the Certificate of Designation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:18:33.943201+00:00","company_name":"Galera Therapeutics, Inc.","ticker":null,"filing_date":"2026-05-19"}]}